Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

empegfilgrastim

A long-acting form and covalent conjugate of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim with 30 kDa polyethylene glycol (PEG), with potential hematopoietic activity. Upon administration, empegfilgrastim acts similarly to endogenous G-CSF and binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Therefore, this agent may prevent the incidence and shorten the duration of chemotherapy-induced neutropenia. Conjugation of the cytokine with a PEG molecule significantly increases this agent's therapeutic half-life compared to filgrastim.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:1-(N-(4-(omega-methoxypoly(oxyethylene))butyl)-L-methionine))human granulocyte colony-stimulating factor (pluripoietin)
Code name:BCD 017
BCD-017
BCD017
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search